NO20030416L - Krystallinsk terapeutisk forbindelse - Google Patents

Krystallinsk terapeutisk forbindelse

Info

Publication number
NO20030416L
NO20030416L NO20030416A NO20030416A NO20030416L NO 20030416 L NO20030416 L NO 20030416L NO 20030416 A NO20030416 A NO 20030416A NO 20030416 A NO20030416 A NO 20030416A NO 20030416 L NO20030416 L NO 20030416L
Authority
NO
Norway
Prior art keywords
therapeutic compound
crystalline therapeutic
crystalline
compound
therapeutic
Prior art date
Application number
NO20030416A
Other languages
English (en)
Other versions
NO20030416D0 (no
NO324220B1 (no
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20030416D0 publication Critical patent/NO20030416D0/no
Publication of NO20030416L publication Critical patent/NO20030416L/no
Publication of NO324220B1 publication Critical patent/NO324220B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20030416A 2000-07-28 2003-01-27 Fremgangsmate for fremstilling av en polymorf NO324220B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (3)

Publication Number Publication Date
NO20030416D0 NO20030416D0 (no) 2003-01-27
NO20030416L true NO20030416L (no) 2003-02-05
NO324220B1 NO324220B1 (no) 2007-09-10

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030416A NO324220B1 (no) 2000-07-28 2003-01-27 Fremgangsmate for fremstilling av en polymorf

Country Status (46)

Country Link
EP (1) EP1305314B1 (no)
JP (1) JP2004505087A (no)
KR (1) KR100457937B1 (no)
CN (1) CN1207297C (no)
AP (1) AP1400A (no)
AR (1) AR032628A1 (no)
AT (1) ATE286901T1 (no)
AU (2) AU7269001A (no)
BG (1) BG107266A (no)
BR (1) BR0112734A (no)
CA (1) CA2417264C (no)
CZ (1) CZ2003126A3 (no)
DE (1) DE60108398T2 (no)
DO (1) DOP2001000217A (no)
DZ (1) DZ3364A1 (no)
EA (1) EA004681B1 (no)
EC (1) ECSP034454A (no)
EE (1) EE200300045A (no)
ES (1) ES2231521T3 (no)
GE (1) GEP20053494B (no)
HK (1) HK1055954A1 (no)
HR (1) HRP20030061A2 (no)
HU (1) HUP0302982A3 (no)
IL (1) IL153226A0 (no)
IN (1) IN2002MU01649A (no)
IS (1) IS6626A (no)
MA (1) MA26931A1 (no)
MX (1) MX233602B (no)
MY (1) MY117831A (no)
NO (1) NO324220B1 (no)
NZ (1) NZ523226A (no)
OA (1) OA12337A (no)
PA (1) PA8523501A1 (no)
PE (1) PE20020277A1 (no)
PH (1) PH12001001922B1 (no)
PL (1) PL365133A1 (no)
PT (1) PT1305314E (no)
SK (1) SK572003A3 (no)
SV (1) SV2001000570A (no)
TN (1) TNSN01112A1 (no)
TW (1) TWI285643B (no)
UA (1) UA72631C2 (no)
UY (1) UY26854A1 (no)
WO (1) WO2002010171A1 (no)
YU (1) YU4703A (no)
ZA (1) ZA200301457B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
MXPA05011643A (es) 2003-04-29 2005-12-15 Pfizer Ltd 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229349C (zh) * 1998-04-20 2005-11-30 美国辉瑞有限公司 吡啶－3－羧酸衍生物
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
DE60108398D1 (de) 2005-02-17
EA004681B1 (ru) 2004-06-24
CN1444585A (zh) 2003-09-24
AU2001272690B2 (en) 2005-12-08
KR100457937B1 (ko) 2004-11-20
MX233602B (es) 2006-01-10
TWI285643B (en) 2007-08-21
ZA200301457B (en) 2004-04-28
YU4703A (sh) 2006-01-16
TNSN01112A1 (fr) 2005-11-10
DOP2001000217A (es) 2002-10-30
HUP0302982A3 (en) 2005-01-28
AP2001002234A0 (en) 2001-09-30
NO20030416D0 (no) 2003-01-27
EP1305314A1 (en) 2003-05-02
MA26931A1 (fr) 2004-12-20
HRP20030061A2 (en) 2003-04-30
CA2417264A1 (en) 2002-02-07
MXPA03000856A (es) 2003-06-06
DE60108398T2 (de) 2005-12-22
SK572003A3 (en) 2004-05-04
IS6626A (is) 2002-11-18
IN2002MU01649A (no) 2004-12-11
PA8523501A1 (es) 2002-10-24
SV2001000570A (es) 2002-09-03
WO2002010171A1 (en) 2002-02-07
PL365133A1 (en) 2004-12-27
NO324220B1 (no) 2007-09-10
GEP20053494B (en) 2005-04-25
OA12337A (en) 2006-05-15
BG107266A (bg) 2003-07-31
PE20020277A1 (es) 2002-05-11
PH12001001922B1 (en) 2006-11-21
HUP0302982A2 (hu) 2003-12-29
EA200300079A1 (ru) 2003-06-26
CA2417264C (en) 2007-06-12
CN1207297C (zh) 2005-06-22
HK1055954A1 (en) 2004-01-30
EP1305314B1 (en) 2005-01-12
UY26854A1 (es) 2002-02-28
MY117831A (en) 2004-08-30
DZ3364A1 (fr) 2002-02-07
ES2231521T3 (es) 2005-05-16
AR032628A1 (es) 2003-11-19
KR20030016430A (ko) 2003-02-26
BR0112734A (pt) 2004-08-10
JP2004505087A (ja) 2004-02-19
IL153226A0 (en) 2003-07-06
NZ523226A (en) 2003-07-25
EE200300045A (et) 2004-12-15
ECSP034454A (es) 2003-03-10
AP1400A (en) 2005-04-28
PT1305314E (pt) 2005-04-29
AU7269001A (en) 2002-02-13
UA72631C2 (uk) 2005-03-15
CZ2003126A3 (cs) 2004-02-18
ATE286901T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DK1451192T3 (da) Ny krystallinsk forbindelse
NO20033205D0 (no) Terapeutiske kromanforbindelser
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
ID29755A (id) Senyawa-senyawa organosilikon
ATE372338T1 (de) Deshalogenverbindungen
NO20030303L (no) Kalsilytiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
TR200100070A3 (tr) Bilesim
NO20030416L (no) Krystallinsk terapeutisk forbindelse
NO20024679L (no) Krystallinsk farmasöytikum
SE0001187D0 (sv) Crystalline form
SE0001422D0 (sv) Crystalline form
SE0004826D0 (sv) Therapeutic compounds
SE0004825D0 (sv) Therapeutic compounds
SE0003368D0 (sv) Therapeutic compounds
SE9904417D0 (sv) Crystalline form
SE0002921D0 (sv) Pharmaceutically useful compounds
SE0002922D0 (sv) Pharmaceutically useful compounds
SE0004458D0 (sv) Pharmaceutically useful compounds
SE0004680D0 (sv) New compound
SE0003477D0 (sv) Compounds
SE0101239D0 (sv) Pharmaceutically useful compounds